AKT1 and Miyoshi myopathy: This ATP-competitive pan-PIM kinase inhibitor has been studied in in vitro and in vivo settings in combination with Akt inhibitor AZD5363 in MM and AML.73 In MM, AZD1897 alone reduced proliferation of MM cell lines but did not have a dramatic effect on cell death, whereas in combination with the Akt inhibitor synergystic cytotoxicity was observed, with >50% cell death.